NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
23.44
-0.55 (-2.27%)
Jul 24, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Transformative Therapies for Cardio-metabolic Diseases
45.56M
Log In
Log In
Transformative Therapies for Cardio-metabolic Diseases Growth
223.37%
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Italy
45.56M
Log In
Log In
Italy Growth
223.37%
Log In
Log In